Lower death rate from colon cancer found in aspirin takers

Aspirin, the mild-mannered pharmaceutical that has burst from the medicine cabinet in recent years as Superdrug, is now tackling cancer: Researchers report today that people who take regular, low doses of aspirin may cut their risk of dying of colon cancer.

The finding is preliminary and already hotly debated, and researchers said it would be premature to recommend aspirin to prevent colon cancer.


But they called the results intriguing, in that they suggest the disease might be controllable with a simple pill.

"It raises the possibility that we might be able to prevent one of the most important cancers in the world through a very simple treatment," said Dr. E. Robert Greenberg, co-author of an editorial published with the study in the New England Journal of Medicine.


The findings arose from an American Cancer Society cancer-prevention study of 662,424 adults who, in 1982, filled out questionnaires on issues such as diet, lifestyle, health and medication use, and then were followed for six years in order to record deaths.

Colon cancer is one of the nation's leading life-threatening malignancies, striking 112,000 people and causing 50,000 deaths a year.

Among people 35 to 74, colorectal cancer is the second leading cause of cancer deaths among men and the third leading cause among women. Only lung and breast cancers are bigger killers.

The researchers found that the regular users of aspirin and other so-called non-steroidal anti-inflammatory drugs such as Bufferin or Anacin were much less likely than others to die of colon cancer.

For those who took at least an aspirin every other day, the fatal colon cancer risk was cut by 40 percent.

Even those who took the drugs less often also appeared to have a significantly reduced risk of dying of colon cancer.

Those who took acetaminophen, an alternative pain killer that does not irritate the stomach, experienced no such benefit.

But the authors say the results are far from conclusive. The study was based on a single self-administered questionnaire.


It did not address the exact dose of aspirin used, and the researchers explored only deaths, not all colon cancer cases.

Furthermore, the reasons for taking aspirin, rather than the medication itself, might conceivably explain the reduced death risk. For example, aspirin takers might see doctors more often and be more likely to have a cancer detected and treated early.

"Our finding is a very interesting research finding but it's premature to start recommending aspirin to reduce the risk of cancer," said Dr. Michael J. Thun of the cancer society, the study's lead author. "There are too many unanswered questions."

One skeptic is Dr. Ronald Ross, a professor at the Kenneth Norris Jr. Comprehensive Cancer Center at the University of Southern California and co-author of an earlier study of 13,987 California retirees that, unlike Dr. Thun's study, found a slightly increased risk of colon cancer among aspirin users.

"I find the magnitude of the effect alone sort of to defy credibility," said Dr. Ross. "They find that people who use aspirin on a regular [even] one-day-a-month basis have a 25 percent reduction [in risk]. That's not credible biologically."

Aspirin has been used for more than 80 years to treat problems such as headache, menstrual pain and muscle ache. It is also used to treat arthritis pain and is often included in cold remedies because it reduces fever.


But over the past four years, a remarkable series of findings have shown aspirin can also prevent first heart attacks, cut down the occurrence of migraine, help reduce the risk of hypertension in late pregnancy and halve the risk of stroke from an irregular heartbeat.

Aspirin is not, however, without nasty side-effects. It can irritate the stomach lining, causing heartburn and nausea. Prolonged use can cause bleeding from the stomach or peptic ulcers, penetrating the wall of the stomach or small intestine.

Researchers say a more sophisticated study is needed. They say there must be a randomized, controlled clinical trial in which two carefully matched groups are followed for years while one group is given aspirin and the other is not.